ECEL1

Across TCGA pan-cancer cohorts, ECEL1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ECEL1 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ECEL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ECEL1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

KIRC, LIHC, and THCA are the cancer types where ECEL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.085	0.881	<.001	46	view →
LIHC	DFS	Median	All	0.081	0.527	.012	9	view →
THCA	DFS	Median	All	0.151	0.813	.009	6	view →
SARC	DFS	Median	All	0.209	0.614	.012	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.377	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ECEL1–KIRC (OS)

Open the KIRC breakdown →